Overview

Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis

Status:
Recruiting
Trial end date:
2022-02-22
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the pharmacokinetics, systemic exposure, safety and tolerability after daily topical application of SKX-16 (Luliconazole 10% Solution) for duration of 29 days in a maximal use setting in adults with moderate to severe distal subungual onychomycosis of the toenails.
Phase:
Phase 1
Details
Lead Sponsor:
SATO Pharmaceutical Co., Ltd.
Treatments:
Luliconazole